US-based biotech firm is latest to reveal impressive results from phase 3 trials of jab

The race for a coronavirus vaccine has received another shot in the arm with the US biotech firm Moderna becoming the latest to reveal impressive results from phase 3 trials of its jab.

An interim analysis released on Monday, and based on 95 patients with confirmed Covid infections, found the candidate vaccine has an efficacy of 94.5%. The company said it now plans to apply to the US regulator, the Food and Drug Administration, for emergency-use authorisation in the coming weeks. In the trial, 90 of the patients received the placebo with the remaining five the vaccine.

Continue reading…

You May Also Like

GCSE results day 2022 live: students discover exam grades amid warning of regional attainment gap

First pupils to sit GCSE exams since before Covid receive their results…